Insulin Human 30/70 Mix Marvel: Withdrawal of the marketing authorisation application

human insulin

Overview

On 20 December 2007, Marvel LifeSciences Ltd. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its applications for marketing authorisations for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel, for the treatment of diabetes mellitus.

  • List item

    Questions and answers on the withdrawal of the marketing authorisation application for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel (PDF/41.87 KB)


    First published: 24/01/2008
    Last updated: 24/01/2008
    EMEA/4193/2008

  • Key facts

    Name
    Insulin Human 30/70 Mix Marvel
    Product number
    EMEA/H/C/000847
    International non-proprietary name (INN) or common name
    • human insulin
    Active substance
    • human insulin
    Date of withdrawal
    20/12/2007
    Company making the application
    Marvel LifeSciences Ltd.
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating